miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy
2018 · Journal of Hematology & Oncology · 128 citations
https://doi.org/10.1186/s13045-018-0600-x
M
Mingzhi Zhang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
356
Papers
5.4K
Citations
38
h-index
143
i10-index
Mingzhi Zhang is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & CAR-T cell therapy research & Viral-associated cancers and disorders. The author has an h-index of 38, co-authored 303 publications.
ORCID: 0000-0003-3581-551XPapers by this author
worksA common variant near TGFBR3 is associated with primary open angle glaucoma
2015 · Human Molecular Genetics · 116 citations
https://doi.org/10.1093/hmg/ddv128
Targeting PD-L1 in non-small cell lung cancer using CAR T cells
2020 · Oncogenesis · 89 citations
https://doi.org/10.1038/s41389-020-00257-z
Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
2020 · Clinical Epigenetics · 83 citations
https://doi.org/10.1186/s13148-020-00962-x
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
2020 · Journal of Hematology & Oncology · 52 citations
https://doi.org/10.1186/s13045-020-00982-3
MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer
2016 · BMC Cancer · 48 citations
https://doi.org/10.1186/s12885-016-2941-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat